Q-Check Pharmaceuticals — Care beyond Healthcare

Early Detection via AI Imaging — Transforming Asymptomatic CAD Screening

Coronary artery disease kills silently. The first symptom, for far too many patients, is a myocardial infarction. AI-powered cardiac imaging is fundamentally changing this equation — enabling detection of significant coronary disease years before the first clinical symptom appears.

AI Coronary Calcium Scoring: Surpassing Human Accuracy

AI-based coronary artery calcium (CAC) scoring now achieves 98.3% accuracy — compared to 89.4% for expert radiologists. This superior accuracy, combined with dramatically reduced processing time, makes AI-augmented CAC screening a scalable population health tool.

FFR-CT: Replacing Invasive Angiography

Coronary CTA with AI-based fractional flow reserve (FFR) prediction achieves 92% concordance with invasive FFR measurement — the gold standard for haemodynamic significance of coronary lesions. This enables accurate assessment of lesion severity without the risk, cost, or patient burden of cardiac catheterisation.

Cost reduction: ₹15,000 AI-CTA versus ₹40,000 for invasive angiography
Accessibility: Non-invasive testing expands screening to outpatient settings

Predictive Models: 5-Year CAD Progression

Machine learning models trained on longitudinal imaging registries are now predicting 5-year CAD progression from baseline imaging data — enabling identification of patients who will develop significant disease before symptoms emerge. Cleveland Clinic data (2024–2025) shows a 40% reduction in acute MIs with AI screening protocol implementation.

Biomarker Integration

High-sensitivity troponin combined with AI imaging creates a multi-modal diagnostic framework that identifies subtle, subclinical CAD with unprecedented accuracy — redefining what "early detection" means in cardiovascular medicine.

Research Sources